Volume 5.11 | Mar 21

Mammary Cell News 5.11 March 21, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
TOP STORY
Met Synergizes with p53 Loss to Induce Mammary Tumors that Possess Features of Claudin-Low Breast Cancer
The MET receptor tyrosine kinase is elevated in triple-negative breast cancer (TNBC) and transgenic Met models (Metmt) develop basal-like tumors. To investigate collaborating events in the genesis of TNBC, scientists generated Metmt mice with conditional loss of murine p53 in mammary epithelia. [Proc Natl Acad Sci USA] Abstract

Apply Now: Mammary Stem Cells Training Course (June 8-9 2013) in Vancouver, Canada.
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Targeting CXCL12/CXCR4 Signaling with Oncolytic Virotherapy Disrupts Tumor Vasculature and Inhibits Breast Cancer Metastases
Because the CXCR4 receptor for the stromal cell-derived factor-1 (CXCL12) chemokine is one of the key stimuli involved in signaling interactions between tumor cells and their stromal microenvironment, investigators used oncolytic virotherapy with a CXCR4 antagonist to target the CXCL12/CXCR4 signaling axis in a triple-negative 4T1 breast carcinoma in syngeneic mice. [Proc Natl Acad Sci USA] Abstract

Estrogen Mediated-Activation of miR-191/425 Cluster Modulates Tumorigenicity of Breast Cancer Cells Depending on Estrogen Receptor Status
Researchers established that the microRNA-191/425 (miR-191/425) cluster is transcriptionally dependent on the host gene, DALRD3, and that the hormone 17β-estradiol (estrogen) controls expression of both miR-191/425 and DALRD3. [PLoS Genet] Full Article

Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer
Scientists investigated the role of matrix metalloproteinases-9 (MMP-9)/tissue inhibitor of metalloproteinases-1 in regulating innate antitumor immunity in breast cancer. [J Immunol] Abstract

Estrogen Increases the Activity of Estrogen Receptor-Negative Breast Cancer Stem Cells through Paracrine Epidermal Growth Factor Receptor and Notch Signaling
Investigators tested the effects of estrogen on cancer stem cell activity in vitro and in vivo and investigated which paracrine signaling pathways locally mediate estrogen effects. [Breast Cancer Res]
Abstract | Full Article

Lipid Metabolism Genes in Contralateral Unaffected Breast and Estrogen Receptor Status of Breast Cancer
The contralateral unaffected breast of women with unilateral breast cancer (cases) is a good model for defining subtype-specific risk because women with estrogen receptor (ER)-negative index primaries are at high risk for subsequent ER-negative primary cancers. Researchers conducted random fine needle aspiration of the unaffected breasts of cases. [Cancer Prev Res] Abstract | Press Release

Short Hairpin RNA Targeting Notch1 Sensitizes Breast Cancer Stem Cell to Paclitaxel
The authors confirmed that paclitaxel enriched breast cancer stem cells (CSCs) in a dose-dependent manner in MCF-7 human breast cancer cell line. They then demonstrated that Notch1 was overexpressed in breast CSCs isolated from paclitaxel-treated MCF-7 cells compared to non-CSCs. [Int J Biochem Cell Biol] Abstract

Pterostilbene, a Bioactive Component of Blueberries, Suppresses the Generation of Breast Cancer Stem Cells within Tumor Microenvironment and Metastasis via Modulating NF-κB/MicroRNA 448 Circuit
Using flowcytometric and Boyden chamber assay, scientists showed MCF7 and MDA-MB-231 cells cocultured with M2 tumor-associated macrophages exhibited increased percentage of CD44+/CD24 cancer stem cell population and migratory/invasive abilities. [Mol Nutr Food Res] Abstract

CLINICAL RESEARCH

Randomized Trial of Lapatinib versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer
This Phase III, randomized, double-blind study assessed the efficacy and safety of lapatinib plus paclitaxel compared with placebo plus paclitaxel in patients with newly diagnosed human epidermal growth factor receptor 2-positive metastatic breast cancer. [J Clin Oncol] Abstract

A Randomized Trial to Assess the Biological Activity of Short-Term (Pre-Surgical) Fulvestrant 500 mg plus Anastrozole versus Fulvestrant 500 mg Alone or Anastrozole Alone on Primary Breast Cancer
In a double-blind, multicenter trial, 121 patients received: fulvestrant 500 mg on day 1 plus anastrozole 1 mg/day for 14-21 days; fulvestrant plus anastrozole placebo; or fulvestrant placebo plus anastrozole, 2-3 weeks before surgery. estrogen-receptor, progesterone-receptor, and Ki67 expression were determined from tumor biopsies before treatment and at surgery. [Breast Cancer Res] Abstract | Full Article

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

REVIEWS
Pharmacogenomics of Breast Cancer Therapy: An Update
Researchers review the data available to date on genomic variants that may influence response to drugs commonly used to treat breast cancer. While none of the variants reported to date have demonstrated clinical utility, ongoing prospective studies and increasing understanding of pharmacogenetics will allow us to better predict risk of toxicity or likelihood of response to specific treatments and to provide a more personalized therapy. [Pharmacol Ther] Abstract
INDUSTRY NEWS

Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
Genedata announced its partnership with EpiFemCare, the European Union-funded research project that will improve the diagnosis and therapy of breast and ovarian cancer. [Genedata AG] Press Release

Dune Medical Devices’ MarginProbe® System Now Available in the United States
Dune Medical Devices, Inc. announced the MarginProbe System, a breakthrough intra-operative tissue assessment device used during lumpectomy surgery to treat early-stage breast cancer, is now available to patients in the United States, with the installation of the first System at University of California, Irvine Medical Center. [PR Newswire Association LLC.] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW The European Cancer Congress (ECCO) 2013
September 27-October 1, 2013
Amsterdam, Netherlands

Visit
our events page to see a complete list of events in the mammary cell community.
JOB OPPORTUNITIES

Research Fellow – Breast Cancer Research (Monash University)

Research Associate – Lung and Breast Cancer Bioinformatics (University College London)

Vice President – Sales and Marketing for Breast and Colon Cancer (Genomic Health)

PhD Studentship – Signal Transduction and Cancer Research (McGill University)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College Medicine)

Postdoctoral Position – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Position – Hypoxia Signaling, Prolyl Hydroxylases and Cancer (UNC-Chapel Hill)

Product Director – Breast Marketing (Genomic Health)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us